Mallinckrodt Medical has acquired U.S. marketing and distributionrights to CEA-Scan, a monoclonal antibody-based imaging agentdeveloped by Immunomedics of Morris Plains, NJ. Mallinckrodt willsell CEA-Scan on a consignment basis for colorectal cancer
Mallinckrodt Medical has acquired U.S. marketing and distributionrights to CEA-Scan, a monoclonal antibody-based imaging agentdeveloped by Immunomedics of Morris Plains, NJ. Mallinckrodt willsell CEA-Scan on a consignment basis for colorectal cancer imagingin the U.S., while Immunomedics will retain manufacturing rights.
Immunomedics has been searching for a partner for CEA-Scansince its North American sales and marketing agreement with AdriaLaboratories of Dublin, OH, was terminated in 1995 after Adriawas acquired by Pharmacia (SCAN 8/16/95). St. Louis-based MallinckrodtMedical makes a nice fit, as its Dutch affiliate MallinckrodtMedical BV has licensing rights to CEA-Scan in Europe.
In other CEA-Scan news, Immunomedics reported last month thatclinical studies of the agent indicate that the product couldbe useful for detecting breast cancer. In a phase II clinicalstudy of 27 patients at the University of Miami Cancer Center,researchers found that CEA-Scan had an accuracy of 81% and a sensitivityof 89% in detecting breast lesions, as compared with surgicalbiopsy.
Immunomedics is planning to begin phase III studies of CEA-Scanfor breast cancer detection later this year. The company is awaitingfinal word from the Food and Drug Administration on its productlicense application for the use of CEA-Scan in detecting colorectalcancer (SCAN 2/28/96).
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.